Alternatives for Reducing Chorea in Huntington Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

119

Participants

Timeline

Start Date

November 12, 2013

Primary Completion Date

August 21, 2017

Study Completion Date

August 21, 2017

Conditions
Chorea Associated With Huntington Disease
Interventions
DRUG

SD-809

SD-809 tablets will be provided in dose strengths of 6, 9 and 12 mg.

Trial Locations (38)

2145

Teva Investigational Site 054, Sydney

10032

Teva Investigational Site 002, New York

11772

Teva Investigational Site 342, Patchogue

12208

Teva Investigational Site 037, Albany

20007

Teva Investigational Site 333, Washington D.C.

21287

Teva Investigational Site 028, Baltimore

27705

Teva Investigational Site 119, Durham

30329

Teva Investigational Site 032, Atlanta

32607

Teva Investigational Site 160, Gainesville

33136

Teva Investigational Site 014, Miami

35233

Teva Investigational Site 057, Birmingham

40202

Teva Investigational Site 087, Louisville

43210

Teva Investigational Site 020, Columbus

45267

Teva Investigational Site 089, Cincinnati

46202

Teva Investigational Site 045, Indianapolis

52242

Teva Investigational Site 024, Iowa City

63110

Teva Investigational Site 027, St Louis

66160

Teva Investigational Site 029, Kansas City

67226

Teva Investigational Site 083, Wichita

72703

Teva Investigational Site 298, Fayetteville

74136

Teva Investigational Site 341, Tulsa

77030

Teva Investigational Site 007, Houston

Teva Investigational Site 199, Houston

80113

Teva Investigational Site 052, Englewood

84108

Teva Investigational Site 100, Salt Lake City

85013

Teva Investigational Site 038, Phoenix

89102

Teva Investigational Site 194, Las Vegas

98034

Teva Investigational Site 220, Kirkland

98108

Teva Investigational Site 096, Seattle

02118

Teva Investigational Site 040, Boston

08103

Teva Investigational Site 328, Camden

08901

Teva Investigational Site 026, New Brunswick

43614-2598

Teva Investigational Site 093, Toledo

37232-2551

Teva Investigational Site 031, Nashville

05401

Teva Investigational Site 137, Burlington

H2L4M1

Teva Investigational Site 098, Montreal

K1G 3G4

Teva Investigational Site 231, Ottawa

M2K 1E1

Teva Investigational Site 300, Toronto

Sponsors
All Listed Sponsors
lead

Auspex Pharmaceuticals, Inc.

INDUSTRY

NCT01897896 - Alternatives for Reducing Chorea in Huntington Disease | Biotech Hunter | Biotech Hunter